Worthy New Immunotherapy Clinical Trial Opens at Johns Hopkins University for Men Thinking of Surgery

As you have probably figured out I am a supporter for the potentiality of immunotherapy in the treatment of prostate cancer. It is a new field with only one drug currently approved for the treatment of prostate cancer, Provenge. The exciting thin about Provenge is not only the real survival advantage that it offers with minimal side effects, but that it is a proof of concept treatment that is heralding in the potential future of many other immunotherapies. Today, we have two new possible treatments in active phase 3 trials, Prostvac and Yervoy. If you search this blog you will [...]